FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia
Abstract Acute myeloid leukemia (AML) has a poor prognosis and high heterogeneity. Most cases of leukemias are caused by environmental factors interacting with the cell’s genetic material, but treatment is still dominated by cell cycle drugs. Therefore, there is an urgent need to find reliable bioma...
Saved in:
Main Authors: | Bo Luo, Wei Li, Jingyuan Zeng, Yingyu Mao, Shuang He, Nan Hu, Qulian Guo, Xiaoli Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-01-01
|
Series: | Discover Oncology |
Online Access: | https://doi.org/10.1007/s12672-025-01738-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Divergent Autologous T Cell Responses to Leukaemic Dendritic Cells during Remission in Acute Promyelocytic Leukaemia
by: Theresia M. Westers, et al.
Published: (2005-01-01) -
Fhl1, a new spatially specific protein, regulates vein graft neointimal hyperplasia
by: Chaoqun Wang, et al.
Published: (2024-12-01) -
Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia
by: Abhishek Mangaonkar, et al.
Published: (2015-01-01) -
NT5E (CD73) as a prognostic biomarker and therapeutic target associated with immune infiltration in lung adenocarcinoma
by: Leyan Chen, et al.
Published: (2025-02-01) -
ANORECTAL PATHOLOGIES IN THE COURSE OF ACUTE LEUKAEMIAS: PREDICTIVE PARAMETERS
by: Fatma Yılmaz, et al.
Published: (2024-08-01)